Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
androgen receptor inhibitor |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L02BB05
|
| gptkbp:brand |
gptkb:Erleada
|
| gptkbp:CASNumber |
956104-40-8
|
| gptkbp:chemicalFormula |
C21H15F4N5O2
|
| gptkbp:developer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
3 days
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Apalutamide
|
| gptkbp:KEGGID |
D10813
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
androgen receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
477.37 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2364609
25154815 DB12001 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
falls
fatigue hypertension fractures hypothyroidism rash |
| gptkbp:UNII |
Q7Z5X6B6F2
|
| gptkbp:usedFor |
prostate cancer
|
| gptkbp:bfsParent |
gptkb:AFP-675
|
| gptkbp:bfsLayer |
7
|